Skip to main content
Clinical Trials/ACTRN12611000166976
ACTRN12611000166976
Not yet recruiting
Phase 2

A randomised controlled trial of a sedative regimen that utilises dexmedetomidine as the primary agent and minimises the use of midazolam compared with current sedation practice in intensive care patients on outcomes of mortality, cognitive function and Health Related Quality of Life.

ANZIC-research centre, Monash University0 sites60 target enrollmentFebruary 11, 2011

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Sedation in intensive care patients
Sponsor
ANZIC-research centre, Monash University
Enrollment
60
Status
Not yet recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 11, 2011
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
ANZIC-research centre, Monash University

Eligibility Criteria

Inclusion Criteria

  • Patients eligible for the study must meet these 2 criteria:
  • The patient is mechanically ventilated via an endotracheal tube and has been intubated, (excluding time spent intubated within an operating or procedural theatre), for less than 12 hours, and the treating clinician believes that:
  • 1\.The patient requires immediate AND ongoing sedative medication for comfort, safety, and to facilitate the delivery of life support measures.
  • 2\.The choice of the sedative medications needs to be determined now
  • 3\.There is uncertainty whether a sedative regimen using dexmedetomidine as the primary agent or the clinicians usual choice of sedative regimen for this patient is superior, AND
  • 4\.The patient is expected to remain intubated the day after tomorrow.

Exclusion Criteria

  • Patients will be excluded from the study if any of the following criteria apply:
  • \- Age less than 18 years,
  • \- Patient is pregnant and/or lactating.
  • \- Patient has a proven or suspected acute primary brain lesion that may result in global impairment of conscious level or cognition, such as traumatic brain injury, intracranial haemorrhage, stroke, or hypoxic brain injury.
  • \- Patient has a proven or suspected cervical spinal cord injury or pathology that may result in permanent or prolonged weakness of upper and lower limbs.
  • \- Patient has proven or suspected primary neurological pathology associated with prolonged weakness, such as Guillain\-Barre syndrome
  • \- Patient has been admitted as a consequence of a drug overdose
  • \- Patient has burn injuries
  • \- Patient is receiving or expected to need ongoing neuromuscular blockade
  • \- Patient has allergy to propofol or dexmedetomidine

Outcomes

Primary Outcomes

Not specified

Similar Trials